Project expected weight loss after vertical sleeve gastrectomy (VSG) by month — %EWL, %TWL, projected BMI, timeline, and comorbidity resolution rates.
The Gastric Sleeve Weight Loss Calculator projects your expected weight loss trajectory after vertical sleeve gastrectomy (VSG), the most commonly performed bariatric surgery worldwide. Based on published meta-analyses tracking thousands of patients over 5+ years, this calculator models the typical %EWL (percent excess weight loss) and %TWL (percent total weight loss) curve from month 1 through year 5.
VSG typically produces 60–70% excess weight loss at 12–18 months, with a gradual 5–10% weight regain by years 3–5. Understanding this trajectory helps patients set realistic expectations and identify early warning signs if their progress deviates significantly from the norm. The calculator also projects your post-surgery BMI at each time point, estimates your reduced basal metabolic rate, and provides evidence-based comorbidity resolution rates for conditions like type 2 diabetes, hypertension, and sleep apnea.
This tool uses the Hamwi formula for ideal body weight and the Mifflin-St Jeor equation for metabolic rate, combined with published VSG outcome data. Whether you're considering surgery, preparing for a pre-operative appointment, or tracking your post-operative progress, this calculator provides the data-driven context you need.
Setting realistic expectations is one of the most important factors in long-term bariatric surgery success. Patients who expect too much too fast may become discouraged during the normal weight loss plateau at 3–6 months. Patients who don't understand the typical regain curve may not recognize early warning signs.
This calculator gives you a month-by-month roadmap based on real outcome data, not marketing promises. It also contextualizes weight loss in terms of BMI milestones and comorbidity resolution, helping you understand the health benefits beyond the number on the scale.
Ideal Body Weight (Hamwi): Male: 106 + 6 × (height_in − 60) lbs Female: 100 + 5 × (height_in − 60) lbs Excess Weight = Current Weight − Ideal Body Weight %EWL = (Weight Lost / Excess Weight) × 100 %TWL = (Weight Lost / Starting Weight) × 100 Projected Weight = Starting Weight − (Starting Weight × %TWL / 100) BMR (Mifflin-St Jeor): 10 × wt_kg + 6.25 × ht_cm − 5 × age + (5 male / −161 female)
Result: At 12 months: 60% EWL, 27% TWL, projected weight 190 lbs, projected BMI 32.6
A 260 lb, 5'4" woman has an ideal weight of 120 lbs by Hamwi, so excess weight is 140 lbs. At 12 months, 60% EWL means she loses about 84 lbs of excess weight. Her projected weight is approximately 176 lbs with BMI dropping from 44.6 to 30.2.
Vertical sleeve gastrectomy (VSG) removes approximately 75–80% of the stomach along its greater curvature, creating a narrow, banana-shaped "sleeve." This achieves weight loss through three mechanisms: restriction (smaller stomach capacity, typically 100–150 mL), hormonal changes (reduced ghrelin production due to removal of the fundus), and faster gastric emptying into the small intestine.
The hormonal component is increasingly recognized as the primary driver of early weight loss and metabolic improvement. Ghrelin, the "hunger hormone," is primarily produced in the gastric fundus that is removed during VSG. Post-operatively, ghrelin levels drop by 60–70%, dramatically reducing appetite. Simultaneously, altered gut hormone signaling (GLP-1, PYY) improves insulin sensitivity and satiety.
The typical VSG weight loss curve follows a predictable pattern: rapid loss months 1–6 (averaging 2–3 lbs/week), gradual loss months 6–18 (averaging 1 lb/week), and a nadir (lowest point) around 12–18 months. After the nadir, most patients experience modest weight regain of 5–10% over the next 2–3 years as the stomach gradually stretches and dietary habits may slip.
This pattern has important implications for goal-setting. Patients should not compare their month-6 rate of loss to their month-12 rate — the deceleration is physiological, not a failure. Similarly, the modest weight regain from nadir is normal and does not mean the surgery has "failed." Success should be measured by maintaining at least 50% EWL at 5 years, which VSG achieves in approximately 70% of patients.
After VSG, patients must commit to lifelong nutritional modifications: daily multivitamins (including B12, iron, calcium, and vitamin D), protein-forward eating (60–80g protein daily), avoidance of high-calorie liquids and grazing behavior, and regular lab work to detect nutritional deficiencies. Iron deficiency is the most common post-VSG deficiency (particularly in menstruating women), followed by B12 and vitamin D.
The reduced stomach capacity means patients can typically eat 1–2 cups of food per meal (compared to 4–6 cups pre-operatively). Meals should prioritize protein first, then vegetables, then complex carbohydrates. Simple sugars and carbonated beverages should be minimized.
On average, patients lose 60–70% of their excess body weight within 12–18 months after VSG. In terms of total body weight, this typically translates to 25–30% loss. For example, a 300 lb patient might expect to lose 75–90 lbs in the first year.
%EWL (percent excess weight loss) measures how much of your weight above your ideal weight you've lost. %TWL (percent total weight loss) measures weight lost as a percentage of your starting weight. Modern bariatric research increasingly uses %TWL because it's simpler and less dependent on arbitrary ideal weight formulas.
Some weight regain is common and expected. Studies show the nadir (lowest weight) is typically reached at 12–18 months, after which 15–20% of patients experience significant weight regain by year 3–5. This is why long-term dietary adherence, physical activity, and follow-up with your bariatric team are essential.
Roux-en-Y gastric bypass typically produces slightly more weight loss (%EWL of 65–75% vs 60–70% for VSG) and higher diabetes remission rates. However, VSG has fewer complications, lower surgical risk, shorter recovery, and no "dumping syndrome." The gap between the two procedures has narrowed in recent years.
Type 2 diabetes improves or resolves in 60–80% of VSG patients, often within weeks — before significant weight loss occurs. This is partly due to hormonal changes (reduced ghrelin, improved GLP-1 signaling) from the surgery itself, not just calorie restriction.
Standard criteria (NIH guidelines): BMI ≥ 40, or BMI ≥ 35 with at least one obesity-related comorbidity (diabetes, hypertension, sleep apnea, etc.). Some insurers and programs now approve metabolic surgery at BMI 30–35 with uncontrolled type 2 diabetes.